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Synopsis/Abstract 
 
Key Points 
 Canine idiopathic hepatitis is a common disease, categorized histologically by 
presence of hepatocellular apoptosis or necrosis, a variable mononuclear or mixed 
inflammatory cell infiltrate, regeneration and fibrosis.  
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prognosis 
 
  Clinical signs are vague and non-specific, but there are known breed, age and gender 
predispositions. 
 Results of clinical pathology are non-specific, but usually include elevations in liver 
enzymes and function impairment; a liver biopsy is required for diagnosis. 
 Management involves around the use of an anti-inflammatory dose of glucocorticoids 
and other supportive and symptomatic therapies including ursodeoxycholic acid, 
antioxidants, diuretics, and diet. 
 The prognosis is variable, but there are known prognostic indicators, especially the 
presence of portal hypertension. 
 
  
 Introduction 
Historically, the term canine chronic hepatitis (CH) has been poorly defined and used to 
describe a variety of inflammatory liver diseases. However, the World Small Animal 
Veterinary Association’s (WSAVA) Liver Standardization Group have relatively recently 
produced standardized criteria for the histological diagnosis of canine liver diseases, 
including CH. They define CH by the presence of hepatocellular apoptosis or necrosis (figure 
1), a variable mononuclear or mixed inflammatory cell infiltrate (Figure 2), regeneration 
(figure 3) and fibrosis (figure 4).1 However, it is clear there are variations in histological 
appearance between breeds.2,3  
 
Hepatic copper accumulation is an important cause of canine CH (please see Hille Fieten and 
Karen Dirksen’s “Canine copper-associated hepatitis,” in this issue). However, for many 
cases where copper accumulation has been ruled out, the cause of CH remains unknown 
despite the patient undergoing a complete diagnostic workup. These dogs are said to have 
idiopathic chronic hepatitis. This article reviews the current theories regarding the 
etiopathogenesis of canine CH other than copper accumulation, as well as the clinical 
features, diagnostic findings, and management of idiopathic CH. 
 
Pathophysiology 
The development of fibrosis is the key pathological change which leads to the development 
of chronic liver disease, including canine idiopathic CH.8 The hepatic stellate cell, also 
known as the Ito cell or lipocyte, is central in the development of ﬁbrosis in humans and 
rats,8-11 and evidence also suggests its involvement in the pathogenesis of hepatic fibrosis in 
dogs.6 Canine hepatic stellate cells reside in the space of Disse, between the sinusoidal 
endothelial cells and the hepatocytes.12 In normal human and rat liver they are the major 
storage site of vitamin A, and also synthesize extracellular matrix components, matrix 
 metalloproteinases, cytokines, and growth factors.8,9 Although their function in canine liver 
has not been extensively studied, they likely possess similar roles. In human chronic liver 
injury they are stimulated to transform into collagen-secreting, activated stellate cells which 
express smooth muscle-specific α-actin, and secrete high-density matrix and collagen into the 
space of Disse.11 In most cases of human and experimental animal chronic liver disease, the 
simulation of stellate cells is believed to be indirect via the release of cytokines from 
inflammatory cells, although some substances act on them directly to stimulate ﬁbrosis.8 For 
instance, activated Kupffer cells in the human liver secrete transforming growth factor β1 
(TGF-β), the most potent ﬁbrogenic factor, and also other cytokines such as platelet-derived 
growth factor.8,11 Inflammatory mediators released from neutrophils, lymphocytes, platelets, 
and necrotic hepatocytes have also been implicated in the pathogenesis of hepatic fibrosis in 
humans,11 but their contribution to the development of fibrosis in canine liver disease has not 
been investigated. Damage to cells and mitochondrial membranes by bile acids in cholestatic 
liver disease also plays a role in producing oxidant damage and stimulating cytokine 
release.13 The formation of fibrous tissue within the liver leads to the development of 
intrahepatic portal hypertension by altering sinusoidal tone and blood flow.9 The 
development of portal hypertension results in many of the complications of chronic liver 
disease such as ascites and gastrointestinal ulceration. 
 
Etiology 
Although there are several known causes of canine CH, the majority of dogs have idiopathic 
disease.3,14,15 A limited number of infectious causes are documented, and include canine 
adenovirus type I (CAV-1)16 and Leptospira spp.17,18 Although initially postulated as a canine 
hepatitis causing virus, the recently identified canine homology of human hepatitis C virus, 
canine hepacivirus (CHV),19 does not appear to be involved in the etiology of canine CH in 
the United Kingdom20 or the Netherlands.21 Although bacteria, especially those originating 
 from the gastrointestinal tract, are known to cause canine cholangitis/cholangiohepatitis,22,23 
their role in the etiology of CH is unknown. Toxins and drug reactions usually cause acute, 
necrotizing hepatitis24 but some such as phenobarbitone can cause CH.25 Defects in copper 
metabolism leading to the development of CH have been described in several breeds of dog. 
These include true ‘copper storage’ disease, where the primary initiating event is a build up 
of copper leading to secondary hepatic damage, and ‘copper-associated’ disease, in which 
copper accumulates secondary to an underlying liver disease including CH. Copper storage 
disease was first described in the Bedlington terrier over three decades ago,26 and since then 
has been reported in the Dalmatian,27 Doberman pinscher,28 and Labrador retriever.29 Further 
details on the role of copper in the etiology of CH can be found in Hille Fieten and Karen 
Dirksen’s “Canine copper-associated hepatitis,” and Penny J Watson’s “Canine Breed 
Specific Hepatopathies,” in this issue. To date, no data exists to convincingly demonstrate the 
presence of an underlying autoimmune etiology to canine CH. Low concentrations of 
antinuclear antibodies were present in some dogs with CH, and the occasional dog had high 
circulating concentrations of antibodies to liver membrane proteins.30 In another study, 10 of 
21 dogs with CH had antibodies to anti-liver membrane protein.31 More recently, 
autoantibodies against liver proteins were found in sera of Doberman pinschers with CH 
before the onset of clinical signs.32 Using an indirect immunofluorescence assay on cryostat 
sections of mouse liver small numbers of Doberman’s with CH had evidence of antinuclear 
antibodies,33 and IgG autoantibodies against histones.34 However, the question that remains 
from all these studies is whether these autoantibodies are the primary cause of the disease, or 
a secondary phenomenon. Finally, the association of certain susceptibility and resistance 
major histocompatibility complex (MHC) class II haplotypes in the Doberman pinschers,35 
and English springer spaniels (ESS)36 clearly indicates a role of the immune system in 
disease development, but does not necessarily point to an autoimmune etiology. 
  
Signalment 
Canine CH is common in the United Kingdom with a reported postmortem prevalence of 
12% in a first opinion practice setting.37 There are several reports of apparent breed, age and 
gender predispositions, although these vary depending on geographic location and also the 
time the study was performed. Moreover, not all dogs in these studies necessarily had 
idiopathic CH, as comprehensive work to eliminate known causes was not always performed. 
An early study performed approximately two decades ago on a Swedish population of dogs, 
and prior to the establishment of the WSAVA criteria for the histological diagnosis of CH, 
demonstrated that the American and English cocker spaniel, West Highland white terrier, 
Labrador retriever, Doberman pinscher and Scottish terrier had an increased risk for CH.38 In 
this study, there was a male predisposition in English and American cocker spaniels which 
were a mean of 5 years old, and female predisposition in Labrador retrievers which were a 
mean of 6.9 years old at presentation. A more recent study performed in the UK assessed for 
breed predilections to CH by comparing the signalment of 551 cases to that of a large control 
population.15 From a total of 61 breeds, the American cocker spaniel, Cairn terrier, 
Dalmatian, Doberman pinscher, English cocker spaniel, English springer spaniel, Great Dane, 
Labrador retriever, and Samoyed were found to be at increased risk for developing CH (see 
Table 1). In this study, the median age for all breeds with CH was 8 years (range, 7 months to 
16 years), and the female to male ratio was 1.5:1.. In Japan, a predilection of female Labrador 
retrievers and Doberman pinschers for CH was reported, and the median age of dogs was 8 
years and 7 months.39 The mean age of 43 dogs with idiopathic CH in one retrospective study 
was 7.7 years (range 0.4 to 14.2 years), although there was no data on apparent breed or 
gender predispositions.3 For further details of breed, age and gender predispositions to canine 
idiopathic CH please see Penny J Watson’s “Canine Breed Specific Hepatopathies,” in this 
 issue.  
 
History and physical examination findings 
The liver has tremendous functional and structural reserve, and a significant loss of normal 
hepatic mass can occur with minimal or no clinical signs.40 The liver also has a remarkable 
capacity to regenerate following hepatic injury, providing the damage is not too severe or 
ongoing,41 and overt liver failure does not develop until at least 70-80% of functional 
capacity is lost.42 Historical signs in dogs with idiopathic CH vary and are usually non-
specific and insidious in onset. The more frequently reported include inappetence, lethargy, 
weight loss, vomiting, and diarrhea.42,43 Some dogs with idiopathic CH can be asymptomatic, 
or alternatively may present with signs of ‘acute’ disease.2 The duration of clinical signs also 
varies, and in 43 dogs with idiopathic CH, were present for a median of 4.3 weeks prior to 
presentation (range, 0.5-14.0 weeks).3 In a study of 101 dogs with both acute hepatitis and 
CH, the most commonly identified signs were lethargy (n=56), anorexia (n=56), vomiting 
(n=48), polyuria and polydipsia (n=27) weight loss (n=28) and diarrhea (n=23).3 In 68 ESS 
with idiopathic CH, clinical signs at presentation included lethargy (n=63), decreased appetite 
(n=58), vomiting (n=34), weight loss (n=31), diarrhea (n=21), and polydipsia (n=21).2 In 16 
Labrador retrievers with CH, signs included vomiting (n=9), lethargy (n=8), weight loss 
(n=6), decreased appetite (n =5), diarrhea (n=2), and polyuria/polydipsia (n=2).44 
 
Physical examination findings are also very variable and likely depend on the duration and 
severity of disease. Physical examination findings in 101 dogs with both acute and CH 
included jaundice (n=24), abdominal distention (n=21), signs of hepatic encephalopathy (HE) 
(n=22), hepatomegaly (n=17), and abdominal pain (n=8).3 Physical examination in 68 ESS 
with idiopathic CH revealed icterus (n=37), hyperthermia (n=24), poor body condition 
(n=23), ascites (n=17), and abdominal pain (n=9).2 A range of concurrent diseases, including 
 those of the endocrine, renal, cardiovascular, musculoskeletal, dermatological and 
neurological systems, are also sometimes documented in dogs with idiopathic CH.2,3 
 
Clinical pathology 
Serum biochemistry 
Clinical pathology is the next step in investigating the dog with suspected idiopathic CH. 
Findings usually include elevations of liver enzyme activities, especially hepatocellular 
enzymes released as a result of liver cell damage, namely alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST). In addition, the markers of cholestasis, alkaline 
phosphatase (ALP) and gamma-glutamyl transferase (GGT) are invariably elevated. There is 
a wide variation in absolute values of the various clinical pathology tests, and very 
occasionally a dog with advanced idiopathic CH may have liver enzyme activity within the 
reference interval. In addition to elevations in liver enzyme activities, due to the development 
of fibrosis, liver function in dogs with idiopathic CH is progressively compromised. Markers 
of reduced liver function include decreased serum albumin, urea, glucose, and coagulation 
factors, while serum bile acids, ammonia and bilirubin may increase. Of course, none of these 
tests are specific for canine idiopathic CH, so should always be interpreted in the light of 
other clinical and clinicopathological findings.  
 
In a variety of breeds of dog with idiopathic CH serum, serum ALP activity was increased in 
32/33 (mean: 660 U/L) and ALT in 16/17 (mean: 403 U/L).3 Albumin was decreased in 
14/24 (mean: 26.0 g/L), and glucose in 2/8 (mean: 4.9 mmol/L). In 32/35 dogs, bile acids 
were increased (mean: 75.7 μmol/L), while resting ammonia was increased in 1/7 dogs 
(mean: 33.9 μmol/l). In 68 ESS with idiopathic CH, serum ALT and ALP activities were 
elevated in all dogs with median values of 690 and 821 U/L, respectively.2 Serum AST and 
 GGT activities were elevated in 75% and 63% of cases with median values of 361 and 26 
U/L. In 76% of cases, resting bile acids were increased with a median of 87 µmol/L, and 
bilirubin was increased in 69% of cases with a median of 77 µmol/L. Albumin and urea, were 
reduced in 38 and 22% of cases, respectively. In 24 Labrador retrievers with CH, all dogs had 
increases in serum activity of one or more hepatobiliary enzyme, with increased ALP (n=21) 
ALT (n=20), AST (n= 20) and GGT (n=9).44 Hyperbilirubinemia and hypoalbuminemia were 
present in 45% and 21% of dogs respectively, pre- or postprandial serum bile acid 
concentrations were increased in 2 of 4 cases, and one of six dogs tested had 
hyperammonemia.44 
 
Hematology 
Non-specific qualitative and quantitative abnormalities in erythrocytes may be present in 
dogs with idiopathic CH, in combination with alterations in white cell and platelet numbers. 
Alterations to red cell morphology may also include the presence of acanthocytes and 
codocytes. Dogs with idiopathic CH may have a neutrophilic leukocytosis, due to stress or an 
inflammatory response, and thrombocytopenia may develop due to platelet sequestration or 
increased destruction.  
 
In 21 dogs with idiopathic CH, the hematocrit was decreased in 11, with a mean of 0.40 L/L 
and thrombocytopenia was identified in 4/10, with a mean platelet count of 212 x109/L.3 
Eleven of 24 dogs had evidence of a leukocytosis (mean: 14.8 x 109/L) with segmented 
neutrophils present in 10/24 dogs. The median white blood cell count was 16.1 × 109/L in 68 
ESS with idiopathic CH, and 77% of cases had an elevated white blood cell count.2 Results 
of hematology from 24 Labrador retrievers with CH included an increased WBC (n=9), 
lymphopenia (n=7), neutropenia (n=2), left shift (n=2), and monocytosis (n=2).44 The median 
 hematocrit was 46%, and seven dogs were anemic (median, 31%; range, 23–35%). Four dogs 
had thrombocytopenia (median: 128 x 103/mL; range, 67– 177 x 103/mL), and one dog had a 
thrombocytosis. 
 
Urinalysis 
Non-specific abnormalities may also be present in the urine of dogs with idiopathic CH, 
including reduced specific gravity as a result of PU/PD, bilirubinuria, and increased 
urobilinogen. Urate crystals are occasionally seen. A paucity of data exists on results of 
urinalysis in dogs with idiopathic CH, but in 14 Labrador retrievers with CH of a variety of 
causes, bilirubinuria was identified in seven dogs, transient glucosuria without hyperglycemia 
in three, and proteinuria in two.44 
 
Hemostasis 
The canine liver plays an important role in maintaining hemostasis, and the resulting 
decreased function in idiopathic CH may result in abnormalities of coagulation (please see 
Cynthia RL Webster’s “Hemostatic Disorders Associated with Hepatobiliary Disease,” in this 
issue). Hepatocytes not only produce fibrinogen, prothrombin and the majority of the 
coagulation factors, but are also responsible for the activation of the vitamin K-dependent 
factors and protein C.45 It is therefore essential to assess coagulation prior to a liver biopsy. In 
humans with chronic hepatocellular disease, levels of vitamin K-dependent clotting factors, 
particularly factor VII and protein C, may decrease.46 However, increased activation may also 
occur in patients with liver diseases and a consumptive coagulopathy, leading to disseminated 
intravascular coagulation (DIC), has been reported in patients with end stage liver disease.46 
 
In one study of dogs with CH of various causes, although both mean prothrombin time (PT) 
 and activated partial thromboplastin time (aPTT) were above upper reference values, only 
PTT was significantly prolonged in dogs with CH and cirrhosis.47 The mean activities of 
factors II, V, VII, VIII, IX, X, XI, and XI activities, and protein C were lower in dogs with 
CH and cirrhosis compared to dogs with CH alone.47 Mean D-dimer concentrations were not 
significantly increased in dogs with CH or CH and cirrhosis.47 In 34 dogs with idiopathic CH, 
an elevated PT (mean: 10.1 seconds) was identified in 14 dogs, an elevated PTT (mean: 17.1 
seconds) in 12, and reduced fibrinogen concentration in eight (mean: 2.5 g/L).3 Prothrombin 
time and aPTT were measured in 49 ESS with idiopathic CH and were increased in 24% and 
21%, respectively.2 Seven of 21 Labrador retrievers with CH had prolonged PTT and nine 
dogs had prolonged PT.44 
 
Diagnostic imaging  
Diagnostic imaging, including abdominal radiography and ultrasonography, is an important 
part of the investigation of a dog with suspected idiopathic CH, and is typically performed in 
combination with clinical pathology. Abdominal radiography can be used to assess liver size, 
position and shape, and to check for the presence of other abdominal pathology.48 As a 
general rule, liver size is reduced in dogs with chronic diseases such as idiopathic CH. 
Splenomegaly may also be present in dogs with CH and portal hypertension. Abdominal 
radiography in dogs with idiopathic CH and ascites secondary to portal hypertension or 
hypoalbuminemia is generally unhelpful because the fluid obscures abdominal detail. 
However, radiographic evaluation is poorly sensitive and specific for the diagnosis of 
idiopathic CH; the liver may appear radiographically normal even when severely diseased. 
Few studies report the radiographic findings in dogs with idiopathic CH, although in 33 ESS, 
27 had reduced liver size and 16 had splenomegaly.2 
 
 Ultrasonography is an established method for examining the canine liver, and it enable an 
assessment of its size, shape, echogenicity and echotexture, as a means of detecting lesions 
affecting the hepatic parenchyma. However, ultrasonography is generally considered 
unsuitable as a sole method for diagnosis because of the large overlap in the ultrasonographic 
appearance between different hepatic diseases, including CH.49,50 In a recent study, a marked 
variability in ultrasonographic appearance of lesions was observed for all diagnoses, 
including hepatitis, and no statistically significant associations between ultrasonographic 
appearance and diagnosis were found.49 The sensitivity for the diagnosis of hepatitis of all 
causes in this latter study was 48%, with 10% of dogs having multifocal hypoechoic 
parenchymal lesions, and 10% showing diffuse parenchymal heterogenicity. Cirrhosis, the 
end stage of idiopathic chronic hepatitis, may be associated with a small, irregularly 
marginated liver; extensive hepatic fibrosis usually results in diffusely increased hepatic 
echogenicity, often with hypoechoic regeneration nodules scattered throughout the 
parenchyma and bulging from the hepatic margins.51 Portal hypertension is a common sequel 
to hepatic fibrosis, resulting in ascites and the development of acquired portosystemic shunts, 
which are occasionally visible on ultrasonographic examination.  
 
In 67 dogs with idiopathic and copper-associated CH, 15 had no identifiable ultrasonographic 
abnormalities, hepatic size was assessed as normal (n=26), small (n=26) and enlarged (n=8).3 
Hepatic structure was found to be normal in 27, irregular in 31, and 11 had increased 
echogenicity. Nodular processes were observed in 16 dogs, and ascites was present in 18. On 
ultrasonographic examination of 68 ESS with CH, the liver appeared small in 49 dogs and 
normal in size in the remainder.2 Changes in hepatic parenchymal echogenicity were present 
in 62 dogs and included hypoechogenicity (n=12), hyperechogenicity (n=10), or a 
combination of hypo- and hyperechogenicity (n=40) when compared with the echogenicity of 
 the spleen. Six dogs had a normal appearance to the liver on ultrasound. 
 
Histopathology 
It is not possible to make a definitive diagnose of idiopathic CH from results of signalment, 
history, physical examination, clinical pathology or diagnostic imaging. In some cases, a 
tentative diagnosis can be made, but the gold standard for diagnosis is the histopathological 
evaluation of liver tissue. This enables subjective descriptors of severity of inflammation and 
a subjective assessment about the amount of fibrosis; these may be used prognostically and 
therapeutically. Histopathology is important to rule out significant copper accumulation as a 
cause of CH. Liver histology will also give vital information to help establish the most 
appropriate therapy, and without a biopsy, therapy of idiopathic CH will be at best non-
specific and at worst counter-productive.  
 
Many methods are available for collection of liver tissue, and the method used will depend on 
clinician preference, availability of equipment, technical skill, cost and the clinical stability of 
the patient (please see Jonathan A. Lidbury’s “Getting the Most out of Liver Biopsy,” in this 
issue). Cytological evaluation of liver aspirates is of limited diagnostic accuracy in the 
diagnosis of idiopathic CH, and is therefore not recommended.52,53 This relates to both the 
importance of liver architecture in the categorization of the diagnosis, and the chances of 
missing inflammatory cells where there are areas of fibrosis or if the distribution is non-
uniform. In one study inflammatory disease was accurately identified cytologically in only 5 
of 20 dogs.53 The only real absolute contraindication for liver biopsy is severe coagulopathy 
(please see Jonathan A. Lidbury’s “Getting the Most out of Liver Biopsy,” in this issue).  
 
Histopathological evaluation should be carried out in accordance with criteria produced by 
 the WSAVA Liver Standardization Group.1 The standard histochemical stain used in the 
assessment of liver tissue is hematoxylin and eosin, but consideration should be given to the 
use of additional stains for specific features such as Masson’s trichrome (connective tissue), 
Perls’ Prussian blue (ferritin), Fouchet’s (bile pigments), and periodic acid-Schiff 
(polysaccharides). In addition, to rule out primary copper accumulation as a cause of CH, 
specific histochemical stains for copper, such as rubeanic acid or rhodanine, should be used, 
especially in at risk breeds. An objective grading and scoring system for CH, akin to those 
used in human medicine,4,5 would enable better characterization of the canine disease to 
improve studies into etiology, response to treatment and prognosis. Although bacteria do not 
appear to be a significant cause of CH, before a diagnosis of the idiopathic disease is made, 
culture of bile or liver tissues could be performed. Although not routinely undertaken, 
fluorescent in situ hybridization (FISH) could also be considered for the identification of 
intra-hepatic bacteria causing CH.55 
 
Findings on histopathological examination will depend on the duration and severity of 
disease. The inflammatory cell infiltrate in dogs with CH has been poorly characterized, 
primarily due to a lack of canine-specific reagents. In one study, high numbers of CD3+ 
lymphocytes were found in liver tissue of dogs with CH,6 although the etiology of these cases 
was not clear. These cells were closely apposed to degenerated hepatocytes and a positive 
correlation between necrosis and the number of portal and lobular CD3+ lymphocytes was 
noted. The hepatic T lymphocyte phenotype has also been characterized in a dog with CH 
before and after treatment.7 Before treatment, numerous CD3+ lymphocytes were present in 
the liver, and the ratio of CD4+/CD8+ was high, and after treatment, CD3+ lymphocyte 
infiltration was reduced along with the ratio of CD4+/CD8+ cells. In ESS with idiopathic 
CH, the predominant inflammatory cell type was the lymphocyte, with all dogs having lesser 
 number of plasma cells.2 Forty-five of 68 dogs also had a neutrophilic inflammatory cell 
infiltrate, but there were always less neutrophils than lymphocytes. The inflammatory cell 
infiltrate was present both in the portal areas and throughout the hepatic parenchyma. In this 
latter study, all dogs had evidence of increased fibrous connective tissue on reticulin staining 
and 38 dogs had bridging fibrosis and of these 22 had cirrhosis. Cases with bridging fibrosis 
had combinations of portal-portal (n=30), portal-central (n=24), and central-central (n=18) 
fibrosis. In 24 Labrador retrievers with CH of various causes, all dogs had mild-to-moderate 
infiltrates of lymphocytes or macrophages, which were most prominent in the portal areas.44 
Thirteen dogs also had a neutrophilic component, and twenty-one had degenerative 
hepatocellular changes. Twenty-one dogs had evidence of increased fibrous tissue on 
hematoxylin and eosin staining, and on examination of Masson’s trichome stained sections, 
six dogs had bridging fibrosis, and four had cirrhosis. In 43 dogs with idiopathic CH, 
cirrhosis was observed in 23, including macronodular cirrhosis in seven.3 
 
Management 
As the etiology of idiopathic CH is currently not understood, specific therapies are not 
possible. Non-specific therapies seem to, however, make a significant difference to the 
quality of life and probably also the survival time of affected dogs. Hepatocytes have a 
remarkable capacity for regeneration, which means that early diagnosis and therapy has the 
potential to reverse disease mechanisms. A key aim of therapy in canine idiopathic CH is to 
inhibit fibrosis, which, if left to progress, will ultimately lead to functional impairment. 
Therapy aimed at addressing clinical signs of liver disease, including ascites, gastrointestinal 
ulceration, and HE is also an important part of therapy of the dog with idiopathic CH. In 
addition, careful dietary management is very important. Unfortunately there is a paucity of 
controlled studies on clinical efficacy and pharmacokinetics of the commonly used drugs in 
 canine idiopathic CH. As a result, many of our current management strategies are either 
derived from human hepatology, from veterinary clinical experience, or originate from low-
quality veterinary clinical studies and anecdotal reports. 
 
Glucocorticoids 
Glucocorticoids have anti-inflammatory, immune-modulating, and antifibrotic properties56. 
They have a potent indirect antifibrotic action via reducing prostaglandin and leucotriene 
production from inflammatory cells, and a weak direct anti-fibrotic action by inhibiting 
mRNA and enzymes. However, glucocorticoids are not without adverse effects, and these can 
be very severe and potentially life-threatening in some dogs with idiopathic CH. Adverse 
effects include increased protein catabolism, fluid retention, gastrointestinal ulceration, an 
increased risk of infection. Glucocorticoids should be used cautiously in dogs with bridging 
fibrosis or cirrhosis, as these changes can be associated with portal hypertension, ascites, 
and/or gastrointestinal ulceration. 
 
There have been limited studies evaluating the use of glucocorticoids in dogs with idiopathic 
CH. In an early study, prednisolone was used in 151 dogs with CH at a dose of 2.2 mg/kg/day 
PO for 7-14 days, and resulted in a significantly increased survival time when compared to 
untreated dogs.57 Moreover, complete remission occurred in some dogs with no relapse. 
However, this study was retrospective and uncontrolled, and it is unknown how many of the 
dogs would fit the criteria for idiopathic CH according to current WSAVA criteria. In a more 
recent study, 36 dogs with idiopathic CH were treated with prednisolone at a dose of 1 
mg/kg/day PO for at least six weeks, and at follow up 11 dogs were in complete remission, 
eight dogs had recurrent clinical signs, and 17 dogs had residual disease. The use of 
glucocorticoids has also been reported in retrospective studies of dogs with idiopathic CH, 
although as it is likely that varying doses were used, and most dogs received other 
 medications, it is difficult to draw conclusions on their efficacy.2,3,44 It appears that clinicians 
are being selective in the cases they treat with glucocorticoids; for instance in a retrospective 
study of 43 dogs with idiopathic CH, prednisone was not used in 12 dogs due to the presence 
of only mild inflammation on histology.3 
 
The results of these studies therefore do support the use of glucocorticoids in dogs with CH. 
In the author’s opinion, glucocorticoids are indicated in the therapy of idiopathic CH when 
there is biopsy evidence of ongoing inflammation and this is associated with mild to 
moderate fibrosis. The glucocorticoid most commonly used is prednisolone rather than 
prednisone, as the latter drug needs to be metabolized into prednisolone by the liver. The 
ideal dose remains unknown, but as there is currently no evidence for an immune-mediated 
etiology for canine CH, an immunosuppressive dose does not appear to be warranted. 
Moreover, this dose is likely to be associated with more severe adverse effects. The author 
currently uses an anti-inflammatory dose of 1 mg/kg/day PO. The duration, or method of 
dose reduction in dogs with idiopathic CH is also not known. In human patients, 
glucocorticoids are continued for at least six months beyond remission, and in some cases 
life-long treatment is given. It is often difficult to assess remission in dogs, particularly as 
glucocorticoids induce hepatic enzymes and so confuse attempts to follow the disease 
clinicopathologically. Repeat liver biopsy can be very useful, although they are infrequently 
performed in our canine patients. The length of therapy therefore remains empirical and some 
animals remain on life-long therapy. In this situation the aim is to use a low alternate day 
dose. There is little data to recommend the use of alternative immune modulating drugs, such 
as azathioprine and cyclosporine, in canine idiopathic CH. 
 
Antifibrotics 
 As detailed above, progressive fibrosis in idiopathic CH ultimately leads to reduced function 
and many of the clinical consequences of advanced liver disease. As yet, there are no widely 
available therapies to inhibit the action of inflammatory cytokines, such as TGF-β, on hepatic 
stellate cells; the main stimulus for fibrous tissue formation. The primary way to inhibit 
fibrosis is to treat the underlying disease mechanism, hence why anti-inflammatory drugs are 
usually indicated in the management of canine idiopathic CH. In addition to the anti-fibrotic 
action of glucocorticoids, other drugs have been reported to have weak direct or indirect anti-
fibrotic actions including zinc and vitamin E.  
 
Colchicine is a more specific antifibrotic; it is an alkaloid that binds to β-tubulin, thus 
inhibiting self-assembly and polymerization of microtubules and interfering with several 
cellular functions.58 In addition, colchicine modulates the production of chemokines and 
prostanoids, inhibits neutrophil and endothelial cell adhesion molecules and eventually it 
decreases neutrophil degranulation, chemotaxis and phagocytosis, thus reducing the initiation 
and amplification of inflammation.59 Although historically it has been used as a hepatic 
antifibrotic in human medicine, in more recent large clinical studies it appears not to be 
effective, and so the hunt still goes on for efficacious antifibrotics.60 There is limited 
evidence of its use in dogs,61,62 and only anecdotal reports of its use in the management of 
idiopathic CH. Adverse effects, including bone marrow suppression, neurological signs, 
anorexia, and diarrhea, are seen relatively commonly. As such, the author does not use 
colchicine in the management of idiopathic CH.  
 
Ursodeoxycholic acid 
Ursodeoxycholic acid (UDCA) is a natural hydrophilic bile acid present in the biliary system, 
but is also synthesized and manufactured commercially. Ursodeoxycholic acid is nontoxic to 
 the liver, whereas the less hydrophilic bile acids such as lithocolic acid can be highly toxic. 
Bile acids exert their toxicity by inducing apoptosis of hepatocytes, and disrupting the 
mitochondrial electron-transport chain leading to the formation of free radicals and oxidative 
damage to cells. Ursodeoxycholic acid exerts its beneficial effects in the liver by preventing 
cells from entering apoptosis and preventing mitochondrial damage, likely by displacing 
toxic hydrophobic bile acids.63-65 Ursodeoxycholic acid is also a cholerectic i.e. it stimulates 
bile flow. In addition it has also been shown to have immune-modulatory actions by reducing 
immunoglobulin and interleukin production and expression of major histocompatibility 
complex-1 on hepatocytes. Studies show an additional anti-oxidant activity of UDCA due to 
increased production of glutathione (GSH).  
 
Although UDCA appears to be used very widely in veterinary practice, little data exists on its 
efficacy in dogs. There is a single case report of a dog with severe cholestasis secondary to 
suspected idiopathic CH whose sole treatment was UDCA.66 In this dog, serum activities of 
liver enzymes and concentrations of cholesterol and total bilirubin all decreased over the 
course of seven months of treatment. Concomitant with this improvement, the composition of 
the serum bile acids changed from the hydrophobic, toxic, endogenous bile acids to the less 
toxic hydrophilic bile acids. Although there are also several retrospective studies of dogs with 
idiopathic CH in which UDCA was used, dogs typically received multiple therapies, making 
it difficult to determine the specific effect of UDCA. At a dose of 15 mg/kg/day PO, UDCA 
appears to be safe, with no adverse effects reported in the literature. As most dogs with 
idiopathic CH have bile stasis, and thus would likely benefit from UDCA, the author uses it 
in all cases.  
 
Antibiotics 
 As bacteria are not involved in the etiology of dogs with idiopathic CH, antibiotics are 
generally not warranted. However, due to compromised reticuloendothelial cell function in 
chronic liver disease,67 bacterial infections may be a secondary complication of idiopathic 
CH. The mainstay of antibiotic use in dogs with idiopathic CH is in the management of HE, 
which arises with the development of portal hypertension and acquired shunts (please see 
Adam G. Gow’s “Hepatic Encephalopathy,” in this issue). In the author’s experience, clinical 
HE is relatively uncommon, even in dogs with advanced liver disease. If there are signs of 
HE, oral antibiotics to suppress bacterial populations that produce gut derived 
encephalopathic toxins are warranted, and these are usually used with lactulose for a 
synergistic effect.68 Suitable antibiotics effective against anaerobic organisms include 
amoxicillin, metronidazole, and neomycin. Metronidazole and amoxicillin have an added 
advantage over neomycin as they are systemically absorbed so may protect against 
bacteremia.  
 
Antioxidants 
Oxidative stress and damage to cells by reactive oxygen species is an important disease 
mechanism. Free radicals take up electrons from neighboring molecules, which results in 
oxidative damage to proteins, lipids, and DNA. In liver disease, oxidant stress is increased 
due to the effects of inflammation, reduced blood flow, and mitochondrial damage by 
refluxed bile acids. Normal cellular protective mechanisms against oxidative damage include 
GSH. Most of the evidence for antioxidants is in acute liver injury, especially that due to 
hepatotoxins.69 Oxidative stress is however likely to be one factor in the pathogenesis of 
idiopathic CH, suggesting antioxidants may have a role in the management of this disease. 
 
Antioxidants include vitamin C, vitamin E, silymarin (silibinin or milk thistle extract) and S-
 adenosyl-L-methionine (SAMe). Vitamin C and E are normally synthesized by dogs, and it is 
not known whether deficiencies occur in canine idiopathic CH and therefore if 
supplementation is beneficial. Silymarin appears to be a strong free-radical scavenger, 
increasing normal cellular defense mechanisms against oxidative damage. In experimental 
laboratory animal studies it has been shown to protect against toxin induced liver damage, 
such as that due to acetaminophen.70 When given intravenously, its beneficial effects have 
also been reported in experimental amanita mushroom toxicity in dogs.71 S-adenosyl-L-
methionine is present in hepatocytes and is a precursor for cysteine, one of the amino acids of 
GSH. S-adenosyl-L-methionine is therefore important in the defense against oxygen free 
radicals. S-adenosyl-L-methionine is produced from methionine, which is activated by SAMe 
synthase in hepatocytes. In liver disease it is therefore possible that the production of SAMe 
and GSH may be reduced, although levels of GSH in canine liver disease vary.72 
Administration of exogenous SAMe could therefore restore levels of GSH in hepatocytes. 
SAMe is also a critical enzyme in many biochemical reactions including the 
transmethylation, transsulfuration, and aminopropylation pathways, so is a key metabolite 
that regulates hepatocyte growth, death and differentiation.73 It is widely available as a 
nutraceutical for dogs, often combined with other antioxidants including silymarin. S-
adenosyl-L-methionine in combination with silymarin has been shown to mitigate the 
apparent pro-oxidant influences of prednisolone74 and minimize the increase in liver enzymes 
in dogs receiving lomustine.75 There are no controlled studies reporting the effects of SAMe 
supplementation in canine idiopathic CH, and there is limited evidence for the efficacy of 
SAMe in human chronic liver disease.76 Having said that, due to the potential for oxidative 
stress and damage, and the fact that adverse effects at therapeutic dosages have not been 
reported, the author sometimes uses combinations of SAMe and silymarin in canine 
idiopathic CH.  
  
Diuretics 
Dogs with idiopathic CH and ascites formation may require diuretic therapy. Ascites is 
usually due to portal hypertension, although in some animals hypoalbuminemia may 
contribute to the pathogenesis.77 Portal hypertension results from an increased intrahepatic 
resistance combined with increased portal blood flow. Increased intrahepatic resistance 
results from fibrous tissue, sinusoidal endothelial dysfunction leading to impaired 
intrahepatic sinusoidal relaxation, and intrahepatic vascular shunts. Fluid is then driven into 
the interstitial space, and when the capacity of the regional lymphatics is overwhelmed, 
ascites develops. The development of ascites is worsened by the splanchnic vasodilation that 
accompanies portal hypertension. The subsequent reduction in systemic arterial blood 
pressure due to pooling of fluid in the abdomen activates the renin-angiotensin-aldosterone 
system (RAAS). Activation of the RAAS then leads to further fluid retention and more 
ascites. Spironolactone, an aldosterone antagonist, is therefore the drug of choice in ascitic 
dogs with idiopathic CH due to portal hypertension, usually at an initial dose of 2 mg/kg PO 
per day. Spironolactone can have a relatively slow onset of activity in humans, taking up to 
14 days to causes diuresis; this may also occur in dogs with idiopathic CH. In cases which are 
refractory to spironolactone, or when a more rapid resolution of ascites is required, 
furosemide (1-2 mg/kg PO q12h) can also be used. However, therapy with furosemide has 
been shown to precipitate more complications in humans with ascites, especially electrolyte 
disturbances such as hypokalemia. 
 
Dietary management 
Appropriate dietary management is as important as drug therapy in the dog with idiopathic 
CH. Each case is individual and the diet should be adjusted accordingly, so clinicians should 
 resist the temptation to think that ‘one diet fits all’. No studies have been performed in dogs 
with idiopathic CH to assess energy needs, or dietary composition, and recommendations are 
usually derived empirically from studies in humans, with most work having been done in 
patients with end-stage liver disease complicated by HE.78 It is the author’s experience that 
many dogs with idiopathic CH are fed diets with inappropriate and excessive protein 
restriction, which may inhibit hepatic regeneration and result in protein-calorie malnutrition. 
Negative protein and energy balance in human patients with chronic liver disease has also 
been linked with abnormal immune responses, sepsis and mortality.79 If energy and protein 
metabolism of dogs with advanced liver disease are similar to those in humans, these patients 
actually have increased protein requirements, possibly two- or threefold maintenance 
values.80 Table 2 summarizes some of the important considerations in the dietary 
management of canine idiopathic CH. 
 
Prognosis 
The prognosis for idiopathic CH is highly variable, and likely dependent on multiple factors, 
especially the stage of disease. The estimated median survival time of 43 dogs with idiopathic 
CH was 18.3 months, with a range of zero to 49 months.3 In Labrador retrievers with CH, the 
median survival was 12.5 months (range, 1 day to 88 months),44 whereas in ESS it was 6.3 
months (range, 1 day to 40.3 months).2 The presence of advanced fibrosis and cirrhosis are 
strongly associated with a reduced survival time in humans with CH, and the presence of 
bridging fibrosis was a predictor of shorter survival time in dogs with CH of varying 
causes.57 Another important prognostic indictor in dogs with CH appears to be the presence 
of ascites; the time from onset of clinical signs to death was two months, compared to 33 
months for dogs without ascites.81 A range of clinical pathology parameters have also been 
associated with a shorter survival time in dogs with CH including prolonged prothrombin 
 time, prolonged partial thromboplastin time, thrombocytopenia, hypoalbuminemia, 
hyperbilirubinuria, and hyperglobulinemia. However caution should be employed when 
interpreting this data in the individual dog with idiopathic CH, as prognosis is dependent on 
multiple variables. 
  
 Figure legends 
Figure 1: Photomicrograph of liver tissue from a Labrador retriever with idiopathic CH 
demonstrating several apoptotic hepatocytes within the hepatic parenchyma (arrows). 
Hematoxylin and eosin. Original magnification x 200. 
 
Figure 2: Photomicrograph of liver tissue from an English springer spaniel with idiopathic 
CH (same case as figure 1) demonstrating a foci of inflammatory cells in the hepatic 
parenchyma (arrow). Hematoxylin and eosin. Original magnification x 100. 
 
Figure 3: Low-power photomicrograph of liver tissue from an English springer spaniel with 
idiopathic CH demonstrating disruption to the normal architecture by regenerative nodules 
(arrows). Hematoxylin and eosin. Original magnification x 40. 
 
Figure 4: Low-power photomicrograph of liver tissue from a Doberman pinscher with 
idiopathic CH demonstrating marked fibrosis (light green staining). Masson’s trichrome. 
Original magnification x 40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 1. Age and gender data for breeds with an increased risk for developing canine CH.  
Breed Odds ratio 
(95% confidence 
interval) 
Median age at diagnosis 
(range) 
Gender 
American 
cocker spaniel 
21.6 (9.7-47.9) 5 years 6 months (2 years 
to 11 years 3 months) 
1F, 5M 
Cairn terrier 3.6 (1.9-6.9) 10 years 2 months (7 years 
to 13 years 5 months) 
4F, 5M 
Dalmatian 4.1 (2.2-7.7) 4 years 7 months (3 years 
to 12 years) 
9F, 1M 
Doberman 
pinscher 
11.5 (7.6-17.3) 5 years 4 months (2 years 6 
months to 10 years) 
16F, 8M 
English 
cocker spaniel 
2.4 (1.8-3.2) 8 years 9 months (1 year 3 
months to 14 years) 
34F, 19M 
English 
springer 
spaniel 
5.3 (4.2-6.7) 5 years (1 year 2 months to 
11 years) 
60F, 20M 
Great Dane 4.0 (1.9-8.9) 6 years 2 months (1 year 2 
months to 7 years 11 
months) 
3F, 3M 
Labrador 
retriever 
2.0 (1.6-2.5) 8 years 3 months (2 year 8 
month to 13 years) 
63F, 32M 
Samoyed 12.6 (5.3-29.9) 10 years (3 years 1 month 
to 11 years) 
2F, 3M 
M, male; F, female. Odds ratios are given based on 2008 control data. 
 
 Table 2. Summary of the dietary recommendations for canine idiopathic CH. 
Palatability and 
frequency 
As dogs with idiopathic CH may be inappetent, feed a palatable diet 
several times per day. Frequent feeding maximizes energy intake and 
helps to reduce the development of hepatic encephalopathy 
Protein As detailed above protein restriction should be avoided in dogs with 
idiopathic CH, and only done if necessary to control signs of hepatic 
encephalopathy. Excessive protein restriction may result in 
protein:calorie malnutrition and the breakdown of highly 
ammoniaogenic endogenous proteins. Feed highly digestible, high 
quality protein such as that from vegetable or casein sources. Regularly 
assess weight, muscle mass and blood albumin 
Carbohydrates Dogs with idiopathic CH may have impaired carbohydrate metabolism, 
so a diet containing highly digestible, complex carbohydrates should be 
fed. 
Fat Normal amounts of fat should be fed, although fat can be restricted if 
steatorrhea develops 
Fiber Fermentable fiber is helpful in dogs with hepatic encephalopathy as it 
acidifies the colon and traps ammonia. It also increases nitrogen 
incorporation into bacteria and reduces bacterial ammonia production. 
Non-fermentable fibre is helpful in preventing constipation, a 
predisposing factor for hepatic encephalopathy. 
Zinc Zinc is essential to large numbers of metalloenzymes involved in a 
range of biochemical processes. Zinc is also involved in membrane 
stability and has free radical and anti-oxidant effects. Zinc metabolism 
may become disrupted in patients with liver disease. Zinc deficiency 
occurs in human CH and may occur in dogs with idiopathic CH, and so 
supplementation may be required.  
Fat-soluble 
vitamins 
These include A, D, E, and K. Malabsorption of fat-soluble vitamins 
can occur with disruption to the enterohepatic circulation of bile acids. 
As detailed above, Vitamin E is an antioxidant and can be 
supplemented in dogs with idiopathic CH. Vitamin K supplementation 
may be necessary if coagulation times are prolonged, especially 
 proceeding biopsy. Vitamins A and D should not probably be 
supplemented as excess Vitamin A can cause hepatic damage and 
excess vitamin D may result in hypercalcaemia. 
Water soluble 
vitamins 
Thiamine (Vitamin B-1) is an essential coenzyme in carbohydrate 
metabolism and deficiency can results in hepatic encephalopathy-like 
signs. Supplementation with Vitamin C is not recommended. 
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